Market Research Logo

Carcinoembryonic Antigen Market Size By Application (Gastrointestinal Cancer [Colon Cancer, Pancreatic Cancer, Rectal Cancer, Liver Cancer, Stomach Cancer, Esophageal Cancer, Gallbladder Cancer, Anal Cancer], Breast Cancer, Lung Cancer, Ovarian Cancer, Pr

Carcinoembryonic Antigen Market Size By Application (Gastrointestinal Cancer [Colon Cancer, Pancreatic Cancer, Rectal Cancer, Liver Cancer, Stomach Cancer, Esophageal Cancer, Gallbladder Cancer, Anal Cancer], Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Thyroid Cancer), By Gender (Male, Female), By End-user (Hospitals, Diagnostic Centers, Cancer Centers, Research and Academic Institutes) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Poland, Russia, Sweden, Switzerland, Netherlands, China, Japan, India, Australia, South Korea, New Zealand, Malaysia, Singapore, Indonesia, Philippines, Brazil, Mexico, Argentina, Columbia, Peru, South Africa, Saudi Arabia, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 - 2024

Carcinoembryonic Antigen Market will reach USD 3.0 billion by 2024; as per a new research report.

Growing cancer prevalence in most of the developing region will be one of the major factors for the carcinoembryonic antigen market growth. According to the Cancer Research UK, it is estimated that globally, there will be 27.5 million new cancer cases each year by 2040. Increasing adoption of unhealthy dietary habits leading to obesity and diabetes has escalated the number of people suffering from cancer. Moreover, government initiatives to increase awareness regarding early detection of cancer will fuel the demand for carcinoembryonic antigen tests, thereby augmenting the industry growth.

Growing demand for effective cancer screening services is one of the major market drivers for carcinoembryonic antigen market growth. Carcinoembryonic antigen tests find its application in diagnosis of various cancers including gastrointestinal cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, and thyroid cancer, thereby driving the global market growth.

Breast cancer market is estimated to grow at a substantial CAGR of 7.3% during the forecast period owing to increasing number of cancer deaths among women suffering from breast cancer leading to increasing demand for early cancer diagnosis. According to GLOBOCAN, there were 14.1 million new cancer cases and 8.2 million deaths worldwide in 2013. The percentage of breast cancer attributes to 11.9% of all forms of cancer that form 1.7 million cases throughout the world.

Males in carcinoembryonic antigen market valued around USD 1,003.2 million in the year 2017, due to lifestyle-related factors such as smoking, drinking alcohol, and excessive weight issues are responsible for the largest share of males in carcinoembryonic antigen market. Also, according to NHS UK, males are 16% more likely to develop cancer and 40% more likely to die from cancer than women, hence driving the market.

Hospitals in carcinoembryonic antigen market is estimated to grow substantially at a CAGR of 6.1% during the forecast timeframe, due to increased geriatric population affected with cancer. Moreover, hospitals have high adoption rates for technologically advanced carcinoembryonic antigen tests that are utilized for cancer diagnosis and management, thereby fueling the growth of market segment.

UK carcinoembryonic antigen market is projected to grow at significant CAGR of 6.7% over the forecast time period. Rapidly increasing geriatric population, technological advancements, and growing healthcare expenditure in the country will promote the market growth.

Some of the leading players in the carcinoembryonic antigen market include F. Hoffmann-La Roche Ltd., Quest Diagnostics, GenWay Biotech Inc., Correlogic Systems, Inc., Creative Diagnostics, Omega Diagnostics Group PLC, RayBiotech, Inc., and Boster Biological Technology. Companies operating in this industry are focusing on strategies such as partnerships, collaborations and new product development to maintain leadership position and expand their product portfolio.


Chapter 1. Methodology
1.1. Methodology
1.2. Market definition
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Carcinoembryonic antigen industry 3600 synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Application trends
2.1.3. Gender trends
2.1.4. End-user trends
2.1.5. Regional trends
Chapter 3. Carcinoembryonic Antigen Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 – 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Rise in cancer prevalence
3.3.1.2. Growing demand for minimally invasive diagnostic procedures
3.3.1.3. Recent technological advancements in carcinoembryonic antigen diagnostics
3.3.1.4. Increasing per capita healthcare expenditure
3.3.2. Industry pitfalls & challenges
3.3.2.1. Inability to detect early stage cancer
3.3.2.2. Lack of awareness regarding the application of carcinoembryonic antigen tests
3.4. Growth potential analysis
3.4.1. By application
3.4.2. By gender
3.4.3. By end-user
3.5. Regulatory landscape
3.5.1. U.S.
3.5.2. Europe
3.6. Global prevalence of top cancers, by region, 2018
3.6.1. North America
3.6.1.1. U.S.
3.6.1.2. Canada
3.6.2. Europe
3.6.2.1. Germany
3.6.2.2. UK
3.6.2.3. France
3.6.2.4. Spain
3.6.2.5. Italy
3.6.2.6. Poland
3.6.2.7. Russia
3.6.2.8. Sweden
3.6.2.9. Switzerland
3.6.2.10. Netherlands
3.6.3. Asia Pacific
3.6.3.1. China
3.6.3.2. Japan
3.6.3.3. India
3.6.3.4. Australia
3.6.3.5. South Korea
3.6.3.6. New Zealand
3.6.3.7. Malaysia
3.6.3.8. Singapore
3.6.3.9. Indonesia
3.6.3.10. Philippines
3.6.4. Latin America
3.6.4.1. Brazil
3.6.4.2. Mexico
3.6.4.3. Argentina
3.6.4.4. Columbia
3.6.4.5. Peru
3.6.5. Middle East and Africa
3.6.5.1. South Africa
3.6.5.2. Saudi Arabia
3.6.5.3. UAE
3.7. Porter’s analysis
3.8. Competitive landscape, 2017
3.8.1. Business overview
3.8.2. Revenue analysis
3.8.3. Product landscape
3.8.4. Strategy dashboard
3.9. PESTEL analysis
Chapter 4. Carcinoembryonic Antigen Market, By Application
4.1. Global carcinoembryonic antigen market share, by application, 2017 & 2024
4.2. Gastrointestinal Cancer
4.2.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.2. Colon Cancer
4.2.2.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.3. Pancreatic Cancer
4.2.3.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.4. Rectal Cancer
4.2.4.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.5. Liver Cancer
4.2.5.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.6. Stomach Cancer
4.2.6.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.7. Esophageal Cancer
4.2.7.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.8. Gallbladder Cancer
4.2.8.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.2.9. Anal Cancer
4.2.9.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.3. Breast Cancer
4.3.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.4. Lung Cancer
4.4.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.5. Ovarian Cancer
4.5.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.6. Prostate Cancer
4.6.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
4.7. Thyroid Cancer
4.7.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
Chapter 5. Carcinoembryonic Antigen Market, By Gender
5.1. Global carcinoembryonic antigen market share, by gender, 2017 & 2024
5.2. Male
5.2.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
5.3. Female
5.3.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
Chapter 6. Carcinoembryonic Antigen Market, By End-user
6.1. Global carcinoembryonic antigen market share, by end-user, 2017 & 2024
6.2. Hospitals
6.2.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
6.3. Diagnostic Centers
6.3.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
6.4. Cancer Centers
6.4.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
6.5. Research and Academic Institutes
6.5.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
6.6. Others
6.6.1. Market estimates and forecast, by region, 2013 – 2024 (USD Million)
Chapter 7. Carcinoembryonic Antigen Market, By Region
7.1. Carcinoembryonic antigen market share, by region, 2017 & 2024
7.2. North America
7.2.1. Market estimates and forecast, by country, 2013 – 2024
7.2.2. Market estimates and forecast, by application, 2013 – 2024
7.2.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.2.3. Market estimates and forecast, by gender, 2013 – 2024
7.2.4. Market estimates and forecast, by end-user, 2013 – 2024
7.2.5. U.S.
7.2.5.1. Market estimates and forecast, by application, 2013 – 2024
7.2.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.2.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.2.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.2.6. Canada
7.2.6.1. Market estimates and forecast, by application, 2013 – 2024
7.2.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.2.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.2.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3. Europe
7.3.1. Market estimates and forecast, by country, 2013 – 2024
7.3.2. Market estimates and forecast, by application, 2013 – 2024
7.3.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.3. Market estimates and forecast, by gender, 2013 – 2024
7.3.4. Market estimates and forecast, by end-user, 2013 – 2024
7.3.5. Germany
7.3.5.1. Market estimates and forecast, by application, 2013 – 2024
7.3.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.6. UK
7.3.6.1. Market estimates and forecast, by application, 2013 – 2024
7.3.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.7. France
7.3.7.1. Market estimates and forecast, by application, 2013 – 2024
7.3.7.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.7.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.7.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.8. Spain
7.3.8.1. Market estimates and forecast, by application, 2013 – 2024
7.3.8.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.8.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.8.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.9. Italy
7.3.9.1. Market estimates and forecast, by application, 2013 – 2024
7.3.9.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.9.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.9.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.10. Poland
7.3.10.1. Market estimates and forecast, by application, 2013 – 2024
7.3.10.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.10.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.10.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.11. Russia
7.3.11.1. Market estimates and forecast, by application, 2013 – 2024
7.3.11.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.11.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.11.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.12. Sweden
7.3.12.1. Market estimates and forecast, by application, 2013 – 2024
7.3.12.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.12.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.12.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.13. Switzerland
7.3.13.1. Market estimates and forecast, by application, 2013 – 2024
7.3.13.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.13.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.13.3. Market estimates and forecast, by end-user, 2013 – 2024
7.3.14. Netherlands
7.3.14.1. Market estimates and forecast, by application, 2013 – 2024
7.3.14.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.3.14.2. Market estimates and forecast, by gender, 2013 – 2024
7.3.14.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4. Asia Pacific
7.4.1. Market estimates and forecast, by country, 2013 – 2024
7.4.2. Market estimates and forecast, by application, 2013 – 2024
7.4.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.3. Market estimates and forecast, by gender, 2013 – 2024
7.4.4. Market estimates and forecast, by end-user, 2013 – 2024
7.4.5. China
7.4.5.1. Market estimates and forecast, by application, 2013 – 2024
7.4.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.6. Japan
7.4.6.1. Market estimates and forecast, by application, 2013 – 2024
7.4.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.7. India
7.4.7.1. Market estimates and forecast, by application, 2013 – 2024
7.4.7.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.7.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.7.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.8. Australia
7.4.8.1. Market estimates and forecast, by application, 2013 – 2024
7.4.8.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.8.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.8.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.9. South Korea
7.4.9.1. Market estimates and forecast, by application, 2013 – 2024
7.4.9.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.9.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.9.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.10. New Zealand
7.4.10.1. Market estimates and forecast, by application, 2013 – 2024
7.4.10.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.10.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.10.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.11. Malaysia
7.4.11.1. Market estimates and forecast, by application, 2013 – 2024
7.4.11.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.11.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.11.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.12. Singapore
7.4.12.1. Market estimates and forecast, by application, 2013 – 2024
7.4.12.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.12.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.12.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.13. Indonesia
7.4.13.1. Market estimates and forecast, by application, 2013 – 2024
7.4.13.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.13.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.13.3. Market estimates and forecast, by end-user, 2013 – 2024
7.4.14. Philippines
7.4.14.1. Market estimates and forecast, by application, 2013 – 2024
7.4.14.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.4.14.2. Market estimates and forecast, by gender, 2013 – 2024
7.4.14.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5. Latin America
7.5.1. Market estimates and forecast, by country, 2013 – 2024
7.5.2. Market estimates and forecast, by application, 2013 – 2024
7.5.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.3. Market estimates and forecast, by gender, 2013 – 2024
7.5.4. Market estimates and forecast, by end-user, 2013 – 2024
7.5.5. Brazil
7.5.5.1. Market estimates and forecast, by application, 2013 – 2024
7.5.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.6. Mexico
7.5.6.1. Market estimates and forecast, by application, 2013 – 2024
7.5.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.7. Argentina
7.5.7.1. Market estimates and forecast, by application, 2013 – 2024
7.5.7.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.7.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.7.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.8. Columbia
7.5.8.1. Market estimates and forecast, by application, 2013 – 2024
7.5.8.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.8.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.8.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.9. Peru
7.5.9.1. Market estimates and forecast, by application, 2013 – 2024
7.5.9.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.5.9.2. Market estimates and forecast, by gender, 2013 – 2024
7.5.9.3. Market estimates and forecast, by end-user, 2013 – 2024
7.5.9.4. Market estimates and forecast, by age group, 2013 – 2024
7.6. Middle East & Africa
7.6.1. Market estimates and forecast, by country, 2013 – 2024
7.6.2. Market estimates and forecast, by application, 2013 – 2024
7.6.2.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.6.3. Market estimates and forecast, by gender, 2013 – 2024
7.6.4. Market estimates and forecast, by end-user, 2013 – 2024
7.6.5. South Africa
7.6.5.1. Market estimates and forecast, by application, 2013 – 2024
7.6.5.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.6.5.2. Market estimates and forecast, by gender, 2013 – 2024
7.6.5.3. Market estimates and forecast, by end-user, 2013 – 2024
7.6.6. Saudi Arabia
7.6.6.1. Market estimates and forecast, by application, 2013 – 2024
7.6.6.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.6.6.2. Market estimates and forecast, by gender, 2013 – 2024
7.6.6.3. Market estimates and forecast, by end-user, 2013 – 2024
7.6.7. UAE
7.6.7.1. Market estimates and forecast, by application, 2013 – 2024
7.6.7.1.1. Market estimates and forecast, by gastrointestinal cancer, 2013 – 2024
7.6.7.2. Market estimates and forecast, by gender, 2013 – 2024
7.6.7.3. Market estimates and forecast, by end-user, 2013 – 2024
Chapter 8. Company Profiles
8.1. F. Hoffmann-La Roche Ltd
8.1.1. Business overview
8.1.2. Financial data
8.1.3. Product landscape
8.1.4. Strategic outlook
8.1.5. SWOT analysis
8.2. Quest Diagnostics
8.2.1. Business overview
8.2.2. Financial data
8.2.3. Product landscape
8.2.4. Strategic outlook
8.2.5. SWOT analysis
8.3. GenWay Biotech Inc.
8.3.1. Business overview
8.3.2. Financial data
8.3.3. Product landscape
8.3.4. Strategic outlook
8.3.5. SWOT analysis
8.4. Correlogic Systems, Inc.
8.4.1. Business overview
8.4.2. Financial data
8.4.3. Product landscape
8.4.4. Strategic outlook
8.4.5. SWOT analysis
8.5. Creative Diagnostics
8.5.1. Business overview
8.5.2. Financial data
8.5.3. Product landscape
8.5.4. Strategic outlook
8.5.5. SWOT analysis
8.6. Omega Diagnostics Group PLC
8.6.1. Business overview
8.6.2. Financial data
8.6.3. Product landscape
8.6.4. Strategic outlook
8.6.5. SWOT analysis
8.7. RayBiotech, Inc.
8.7.1. Business overview
8.7.2. Financial data
8.7.3. Product landscape
8.7.4. Strategic outlook
8.7.5. SWOT analysis
8.8. Boster Biological Technology
8.8.1. Business overview
8.8.2. Financial data
8.8.3. Product landscape
8.8.4. Strategic outlook
8.8.5. SWOT analysis
Data Tables
TABLE 1. Carcinoembryonic antigen industry 3600 synopsis, 2013 – 2024
TABLE 2. Global carcinoembryonic antigen market, 2013 – 2017 (USD Million)
TABLE 3. Global carcinoembryonic antigen market, 2018 – 2024 (USD Million)
TABLE 4. Global carcinoembryonic antigen market, by application, 2013 – 2017 (USD Million)
TABLE 5. Global carcinoembryonic antigen market, by application, 2018 – 2024 (USD Million)
TABLE 6. Global carcinoembryonic antigen market, by gender, 2013 – 2017 (USD Million)
TABLE 7. Global carcinoembryonic antigen market, by gender, 2018 – 2024 (USD Million)
TABLE 8. Global carcinoembryonic antigen market, by end-user, 2013 – 2017 (USD Million)
TABLE 9. Global carcinoembryonic antigen market, by type, 2018 – 2024 (USD Million)
TABLE 10. Global carcinoembryonic antigen market, by region, 2013 – 2017 (USD Million)
TABLE 11. Global carcinoembryonic antigen market, by region, 2018 – 2024 (USD Million)
TABLE 12. Industry impact forces
TABLE 13. U.S. cancer prevalence, 2018
TABLE 14. Canada cancer prevalence, 2018
TABLE 15. Germany cancer prevalence, 2018
TABLE 16. UK cancer prevalence, 2018
TABLE 17. France cancer prevalence, 2018
TABLE 18. Spain cancer prevalence, 2018
TABLE 19. Italy cancer prevalence, 2018
TABLE 20. Poland cancer prevalence, 2018
TABLE 21. Russia cancer prevalence, 2018
TABLE 22. Sweden cancer prevalence, 2018
TABLE 23. Switzerland cancer prevalence, 2018
TABLE 24. The Netherlands cancer prevalence, 2018
TABLE 25. China cancer prevalence, 2018
TABLE 26. Japan cancer prevalence, 2018
TABLE 27. India cancer prevalence, 2018
TABLE 28. Australia cancer prevalence, 2018
TABLE 29. South Korea cancer prevalence, 2018
TABLE 30. New Zealand cancer prevalence, 2018
TABLE 31. Singapore cancer prevalence, 2018
TABLE 32. Singapore cancer prevalence, 2018
TABLE 33. Indonesia cancer prevalence, 2018
TABLE 34. Philippines cancer prevalence, 2018
TABLE 35. Brazil cancer prevalence, 2018
TABLE 36. Mexico cancer prevalence, 2018
TABLE 37. Argentina cancer prevalence, 2018
TABLE 38. Columbia cancer prevalence, 2018
TABLE 39. Peru cancer prevalence, 2018
TABLE 40. South Africa cancer prevalence, 2018
TABLE 41. Saudi Arabia cancer prevalence, 2018
TABLE 42. UAE cancer prevalence, 2018
TABLE 43. Gastrointestinal cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 44. Gastrointestinal cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 45. Colon cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 46. Colon cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 47. Pancreatic cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 48. Pancreatic cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 49. Rectal cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 50. Rectal cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 51. Liver cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 52. Liver cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 53. Stomach cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 54. Stomach cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 55. Esophageal cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 56. Esophageal cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 57. Gallbladder cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 58. Gallbladder cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 59. Anal cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 60. Anal cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 61. Breast cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 62. Breast cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 63. Lung cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 64. Lung cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 65. Ovarian cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 66. Ovarian cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 67. Prostate cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 68. Prostate cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 69. Thyroid cancer market size, by region, 2013 – 2024 (USD Million)
TABLE 70. Thyroid cancer market size, by region, 2018 – 2024 (USD Million)
TABLE 71. Male market size, by region, 2013 – 2024 (USD Million)
TABLE 72. Male market size, by region, 2018 – 2024 (USD Million)
TABLE 73. Female market size, by region, 2013 – 2024 (USD Million)
TABLE 74. Female market size, by region, 2018 – 2024 (USD Million)
TABLE 75. Hospitals market size, by region, 2013 – 2024 (USD Million)
TABLE 76. Hospitals market size, by region, 2018 – 2024 (USD Million)
TABLE 77. Diagnostic centers market size, by region, 2013 – 2024 (USD Million)
TABLE 78. Diagnostic centers market size, by region, 2018 – 2024 (USD Million)
TABLE 79. Cancer centers market size, by region, 2013 – 2024 (USD Million)
TABLE 80. Cancer centers market size, by region, 2018 – 2024 (USD Million)
TABLE 81. Research and academic institutes market size, by region, 2013 – 2024 (USD Million)
TABLE 82. Research and academic institutes market size, by region, 2018 – 2024 (USD Million)
TABLE 83. Others market size, by region, 2013 – 2024 (USD Million)
TABLE 84. Others market size, by region, 2018 – 2024 (USD Million)
TABLE 85. North America carcinoembryonic antigen market size, by country, 2013 - 2024 (USD Million)
TABLE 86. North America carcinoembryonic antigen market size, by country, 2018 – 2024 (USD Million)
TABLE 87. North America carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
TABLE 88. North America carcinoembryonic antigen market size, by application, 2018 - 2024 (USD Million)
TABLE 89. North America carcinoembryonic antigen market size, by gastrointestinal cancer, 2013 - 2027 (USD Million)
TABLE 90. North America carcinoembryonic antigen market size, by gastrointestinal cancer, 2018 - 2024 (USD Million)
TABLE 91. North America carcinoembryonic antigen market size, by gender, 2013 - 2027 (USD Million)
TABLE 92. North America carcinoembryonic antigen market size, by gender, 2018 - 2024 (USD Million)
TABLE 93. North America carcinoembryonic antigen market size, by end-user, 2013 - 2027 (USD Million)
TABLE 94. North America carcinoembryonic antigen market size, by end-user, 2018 - 2024 (USD Million)
TABLE 95. U.S. carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
TABLE 96. U.S. carcinoembryonic antigen market size, by application, 2018 - 2024 (USD Million)
TABLE 97. U.S. carcinoembryonic antigen market size, by gastrointestinal cancer, 2013 - 2027 (USD Million)
TABLE 98. U.S. carcinoembryonic antigen market size, by gastrointestinal cancer, 2018 - 2024 (USD Million)
TABLE 99. U.S. carcinoembryonic antigen market size, by gender, 2013 - 2027 (USD Million)
TABLE 100. U.S. carcinoembryonic antigen market size, by gender, 2018 - 2024 (USD Million)
TABLE 101. U.S. carcinoembryonic antigen market size, by end-user, 2013 - 2027 (USD Million)
TABLE 102. U.S. carcinoembryonic antigen market size, by end-user, 2018 - 2024 (USD Million)
TABLE 103. Canada carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
TABLE 104. Canada carcinoembryonic antigen market size, by application, 2018 - 2024 (USD Million)
TABLE 105. Canada carcinoembryonic antigen market size, by gastrointestinal cancer, 2013 - 2027 (USD Million)
TABLE 106. Canada carcinoembryonic antigen market size, by gastrointestinal cancer, 2018 - 2024 (USD Million)
TABLE 107. Canada carcinoembryonic antigen market size, by gender, 2013 - 2027 (USD Million)
TABLE 108. Canada carcinoembryonic antigen market size, by gender, 2018 - 2024 (USD Million)
TABLE 109. Canada carcinoembryonic antigen market size, by end-user, 2013 - 2027 (USD Million)
TABLE 110. Canada carcinoembryonic antigen market size, by end-user, 2018 - 2024 (USD Million)
TABLE 111. Europe carcinoembryonic antigen market size, by country, 2013 - 2024 (USD Million)
TABLE 112. Europe carcinoembryonic antigen market size, by country, 2018 – 2024 (USD Million)
TABLE 113. Europe carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
TABLE 114. Europe carcinoembryonic antigen market size, by application, 2018 - 2024 (USD Million)
TABLE 115. Europe carcinoembryonic antigen market size, by gastrointestinal cancer, 2013 - 2027 (USD Million)
TABLE 116. Europe carcinoembryonic antigen market size, by gastrointestinal cancer, 2018 - 2024 (USD Million)
TABLE 117. Europe carcinoembryonic antigen market size, by gender, 2013 - 2027 (USD Million)
TABLE 118. Europe carcinoembryonic antigen market size, by gender, 2018 - 2024 (USD Million)
TABLE 119. Europe carcinoembryonic antigen market size, by end-user, 2013 - 2027 (USD Million)
TABLE 120. Europe carcinoembryonic antigen market size, by end-user, 2018 - 2024 (USD Million)
TABLE 121. Germany carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
TABLE 122. Germany carcinoembryonic antigen market size, by application, 2018 - 2024 (USD Million)
TABLE 123. Germany carcinoembryonic antigen market size, by gastrointestinal cancer, 2013 - 2027 (USD Million)
TABLE 124. Germany carcinoembryonic antigen market size, by gastrointestinal cancer, 2018 - 2024 (USD Million)
TABLE 125. Germany carcinoembryonic antigen market size, by gender, 2013 - 2027 (USD Million)
TABLE 126. Germany carcinoembryonic antigen market size, by gender, 2018 - 2024 (USD Million)
TABLE 127. Germany carcinoembryonic antigen market size, by end-user, 2013 - 2027 (USD Million)
TABLE 128. Germany carcinoembryonic antigen market size, by end-user, 2018 - 2024 (USD Million)
TABLE 129. UK carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
TABLE 130. UK carcinoembryonic antigen market size, by application, 2018 - 2024 (USD Million)
TABLE 131. UK carcinoembryonic antigen market size, by gastrointestinal cancer, 2013 - 2027 (USD Million)
TABLE 132. UK carcinoembryonic antigen market size, by gastrointestinal cancer, 2018 - 2024 (USD Million)
TABLE 133. UK carcinoembryonic antigen market size, by gender, 2013 - 2027 (USD Million)
TABLE 134. UK carcinoembryonic antigen market size, by gender, 2018 - 2024 (USD Million)
TABLE 135. UK carcinoembryonic antigen market size, by end-user, 2013 - 2027 (USD Million)
TABLE 136. UK carcinoembryonic antigen market size, by end-user, 2018 - 2024 (USD Million)
TABLE 137. France carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
TABLE 138. France carcinoembryonic antigen market size, by application, 2018 - 2024 (USD Million)
TABLE 139. France carcinoembryonic antigen market size, by gastrointestinal cancer, 2013 - 2027 (USD Million)
TABLE 140. France carcinoembryonic antigen market size, by gastrointestinal cancer, 2018 - 2024 (USD Million)
TABLE 141. France carcinoembryonic antigen market size, by gender, 2013 - 2027 (USD Million)
TABLE 142. France carcinoembryonic antigen market size, by gender, 2018 - 2024 (USD Million)
TABLE 143. France carcinoembryonic antigen market size, by end-user, 2013 - 2027 (USD Million)
TABLE 144. France carcinoembryonic antigen market size, by end-user, 2018 - 2024 (USD Million)
TABLE 145. Spain carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
TABLE 146. Spain carcinoembryonic antigen market size, by application, 2018 - 2024 (USD Million)
TABLE 147. Spain carcinoembryonic antigen market size, by gastrointestinal cancer, 2013 - 2027 (USD Million)
TABLE 148. Spain carcinoembryonic antigen market size, by gastrointestinal cancer, 2018 - 2024 (USD Million)
TABLE 149. Spain carcinoembryonic antigen market size, by gender, 2013 - 2027 (USD Million)
TABLE 150. Spain carcinoembryonic antigen market size, by gender, 2018 - 2024 (USD Million)
TABLE 151. Spain carcinoembryonic antigen market size, by end-user, 2013 - 2027 (USD Million)
TABLE 152. Spain carcinoembryonic antigen market size, by end-user, 2018 - 2024 (USD Million)
TABLE 153. Italy carcinoembryonic antigen market size, by application, 2013 - 2027 (USD Million)
Tables
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report